James Berenson, MD, is the Chief Executive Officer at Berenson Cancer Center, President at ONCOtracker, Inc, West Hollywood, CA, and President & Scientific Director at the Institute for Myeloma & Bone Cancer Research in West Hollywood, CA.
Dr Berenson obtained his doctorate in medicine from the University of California, San Diego, CA, after which he completed his internship and residency in internal medicine at the University of Utah Medical Center in Salt Lake City, UT. Dr Berenson then completed a fellowship in hematology/oncology at the University of California at Los Angeles (UCLA) in Los Angeles, CA.
Dr Berenson is affiliated with the Multiple Myeloma Research Foundation and the International Myeloma Foundation.
Speaking on multiple myeloma and metastatic bone disease
Whilst his primary areas of research interest are in myeloma and metastatic bone disease, Dr Berenson also studies antibodies, T-cell receptors, cytokines, cancer genes, viruses and blood vessel development.
Dr Berenson has recently been involved in clinical trials involving combination regimens for the treatment of relapsed and refractory multiple myeloma, such as a Phase I trial of ruxolitinib, lenalidomide and steroids, and a Phase I/II trial assessing bortezomib and melphalan combination therapy.